Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|June 2, 2020
- Pharmaceutical Technology-06-02-2020
- Volume 44
- Issue 6
Triple Shaft Mixer with Powder Induction Manifold
The 600-gallon VersaMix Model VM-600 from Ross is qualified for high-speed subsurface powder induction with a proprietary Ross Solids/Liquid Injection Manifold (SLIM).
The 600-gallon VersaMix Model VM-600 from Ross is qualified for high-speed subsurface powder induction with a proprietary Ross Solids/Liquid Injection Manifold (SLIM). The SLIM function allows for the incorporation of powder or liquid phases into the rotor-stator mix head, causing instant wet-out as it rotates at 3600 RPM.
Available in laboratory sizes up to 4000 gallons, the mixer uses a dual-post triple-shaft design for the processing of substantial powder phases along with an anchor agitator to move the product from the high shear rotor stator head to a high-speed dispersing head, which deagglomerates any remaining fisheyes. The SLIM feature also enables the device to mix large batches and accelerate loading phases.
Articles in this issue
over 6 years ago
What’s Next in Air Transportation for Clinical Trial Logisticsover 6 years ago
2019 Investments Centered around Cell and Gene Therapiesover 6 years ago
Generic Drugs in Spotlight as Pandemic Creates Shortagesover 6 years ago
Are We All In This Together?over 6 years ago
Following Guidelines During a Crisisover 6 years ago
Intelligent Packaging Promotes Interaction with Patientsover 6 years ago
Why Do Disinfectant Residues Matter?over 6 years ago
Formulating for Convenience and Complianceover 6 years ago
Reducing Risk with Abuse‑Deterrent Formulationsover 6 years ago
Better Connected: The Value of Connected Drug DeliveryRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5